These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24628852)

  • 21. The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome.
    Seow KM; Ting CH; Huang SW; Ho LT; Juan CC
    Taiwan J Obstet Gynecol; 2018 Oct; 57(5):696-704. PubMed ID: 30342654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway.
    Qiu Z; Dong J; Xue C; Li X; Liu K; Liu B; Cheng J; Huang F
    J Ethnopharmacol; 2020 Mar; 250():111965. PubMed ID: 31185267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis.
    Welt CK; Taylor AE; Fox J; Messerlian GM; Adams JM; Schneyer AL
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5582-7. PubMed ID: 16030174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ameliorative effects of marjoram in dehydroepiandrosterone induced polycystic ovary syndrome in rats.
    Rababa'h AM; Matani BR; Ababneh MA
    Life Sci; 2020 Nov; 261():118353. PubMed ID: 32877649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome.
    Abramovich D; Irusta G; Bas D; Cataldi NI; Parborell F; Tesone M
    Endocrinology; 2012 Jul; 153(7):3446-56. PubMed ID: 22577112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of Heqi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway.
    Zhao H; Zhou D; Chen Y; Liu D; Chu S; Zhang S
    Daru; 2017 Oct; 25(1):21. PubMed ID: 29020999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
    Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
    Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome.
    Zhang C; Ma J; Wang W; Sun Y; Sun K
    Hum Reprod; 2018 Nov; 33(11):2096-2106. PubMed ID: 30272163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Curcumin-loaded super-paramagnetic iron oxide nanoparticle affects on apoptotic factors expression and histological changes in a prepubertal mouse model of polycystic ovary syndrome-induced by dehydroepiandrosterone - A molecular and stereological study.
    Fatemi Abhari SM; Khanbabaei R; Hayati Roodbari N; Parivar K; Yaghmaei P
    Life Sci; 2020 May; 249():117515. PubMed ID: 32147428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of γ-linolenic acid on Polycystic Ovary Syndrome associated Focal Segmental Glomerulosclerosis via TGF-β pathway.
    D Prabhu Y; Bhati M; Vellingiri B; Valsala Gopalakrishnan A
    Life Sci; 2021 Jul; 276():119456. PubMed ID: 33811895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paeoniflorin attenuates DHEA-induced polycystic ovary syndrome via inactivation of TGF-β1/Smads signaling pathway
    Zhou J; Tan Y; Wang X; Zhu M
    Aging (Albany NY); 2021 Feb; 13(5):7084-7095. PubMed ID: 33638949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrantly increased mRNA expression of betaglycan, an inhibin co-receptor in the ovarian tissues in women with polycystic ovary syndrome.
    Zhu R; Zhou X; Chen Y; Qiu C; Xu W; Shen Z
    J Obstet Gynaecol Res; 2010 Feb; 36(1):138-46. PubMed ID: 20178540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
    Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
    Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D3 affects mitochondrial biogenesis through mitogen-activated protein kinase in polycystic ovary syndrome mouse model.
    Safaei Z; Bakhshalizadeh S; Nasr-Esfahani MH; Akbari Sene A; Najafzadeh V; Soleimani M; Shirazi R
    J Cell Physiol; 2020 Sep; 235(9):6113-6126. PubMed ID: 32048305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The phytoestrogen, quercetin, in serum, uterus and ovary as a potential treatment for dehydroepiandrosterone-induced polycystic ovary syndrome in the rat.
    Jafari Khorchani M; Zal F; Neisy A
    Reprod Fertil Dev; 2020 Feb; 32(3):313-321. PubMed ID: 31661670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of vitamin D on ovary in DHEA-treated PCOS rat model: A light and electron microscopic study.
    Çelik LS; Kuyucu Y; Yenilmez ED; Tuli A; Dağlıoğlu K; Mete UÖ
    Ultrastruct Pathol; 2018; 42(1):55-64. PubMed ID: 29192811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic inflammation, cellular influx and up-regulation of ovarian VCAM-1 expression in a mouse model of polycystic ovary syndrome (PCOS).
    Solano ME; Sander VA; Ho H; Motta AB; Arck PC
    J Reprod Immunol; 2011 Dec; 92(1-2):33-44. PubMed ID: 22018827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nontargeted metabolomic analysis of skeletal muscle in a dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome.
    Shen Q; Bi H; Yu F; Fan L; Zhu M; Jia X; Kang J
    Mol Reprod Dev; 2019 Apr; 86(4):370-378. PubMed ID: 30633842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effects of minocycline on the ovary of polycystic ovary syndrome mouse model: Molecular docking analysis and evaluation of TNF-α, TNFR2, TLR-4 gene expression.
    Khajouei A; Hosseini E; Abdizadeh T; Kian M; Ghasemi S
    J Reprod Immunol; 2021 Apr; 144():103289. PubMed ID: 33610928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.